



MEDICAL TIPS

DIABIZ TABLETS

Issue II, No. 7, 2022

Frequency of Urinary Tract Infections (UTIs) in Type 2 Diabetic Patients Taking Dapagliflozin

Khan S et al. Cureus 2022; 14(1): e21720.

- UTIs are common in diabetic patients and the use of SGLT2 inhibitors increase the glucose levels in the urine which further enhances the risk of UTIs.
- A cross-sectional study on 400 diabetic patients receiving 5/10mg of dapagliflozin showed that the prevalence of UTIs was 5.3%.
- The prevalence was higher in the elderly, especially women with no association to the dose strength of dapagliflozin.
- These infections were observed to be mild to moderate and were easily treated.

The UTIs in patients on dapagliflozin were mild to moderate, were treated easily and did not cause the patient to discontinue the treatment, thus concluding that dapagliflozin is well tolerated in patients with diabetes.

